GALT GALECTIN THERAPEUTICS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1133416 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY37.8%
TTM EPS YoY45.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-179.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets357.0%
Debt / equity—
Current ratio0.28x
Interest coverage-2.20x
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-66.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.56M | $2.13M | $2.23M | $1.93M | $2.61M | $3.26M | $6.49M | $11.11M |
| SG&A expense | $1.80M | $1.85M | $1.85M | $1.43M | $1.59M | $1.36M | $1.41M | $1.32M |
| Operating income | -$3.37M | -$3.98M | -$4.08M | -$3.37M | -$4.20M | -$4.62M | -$7.90M | -$12.43M |
| Interest expense | $786,000 | $2.00M | $1.99M | $1.94M | $1.82M | $1.83M | $1.74M | $1.73M |
| Net income | -$3.53M | -$9.11M | -$5.05M | -$5.50M | -$8.18M | -$7.52M | -$9.63M | -$11.97M |
| EPS (basic) | -0.04 | -0.14 | -0.08 | — | -0.13 | -0.12 | -0.15 | — |
| EPS (diluted) | -0.04 | -0.14 | -0.08 | — | -0.13 | -0.12 | -0.15 | — |
| Weighted avg. shares (diluted) | 89.62M | 65.88M | 65.78M | — | 64.20M | 63.45M | 63.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $11.71M | $13.27M | $14.11M | $17.72M | $11.53M | $13.77M | $7.43M | $15.12M |
| Current assets | $12.90M | $14.66M | $15.69M | $19.44M | $12.73M | $15.43M | $9.29M | $17.25M |
| PP&E, net | — | — | — | $0 | — | — | — | $0 |
| Total assets | $13.01M | $14.83M | $15.76M | $19.53M | $12.87M | $15.60M | $9.53M | $17.50M |
| Current liabilities | $46.41M | $151.62M | $7.31M | $8.03M | $136.44M | $10.77M | $110.84M | $35.41M |
| Total liabilities | $46.45M | $151.68M | $146.00M | $145.73M | $136.44M | $132.77M | $121.79M | $120.56M |
| Shareholders' equity | -$35.16M | -$138,575 | -$131.96M | -$127.92M | -$125.30M | -$118.89M | -$113.98M | -$104.79M |
| Shares outstanding | 100.88M | 66.31M | 65.86M | 65.20M | 64.47M | 64.06M | 63.29M | 63.16M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.27M | -$2.44M | -$3.87M | -$6.04M | -$3.54M | -$6.60M | -$7.69M | -$12.79M |
| Financing cash flow | $702,000 | $1.60M | $257,000 | $12.24M | $1.30M | $12.94M | $0 | $851,000 |
| Stock-based compensation | $949,000 | $963,000 | $686,000 | $195,000 | $498,000 | $500,000 | $468,000 | $590,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.